A review of adherence to drug therapy in patients with overactive bladder.
about
Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?To what extent are national guidelines for the management of urinary incontinence in women adhered? Data from a national audit.Tolterodine extended-release for overactive bladder.The potential role of stem cells in the treatment of urinary incontinence.Medication adherence in the management of nocturia: challenges and solutions.Patients with medication-refractory OAB symptoms should be further treated with neuromodulationValidation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.Factors affecting medication discontinuation in patients with overactive bladder symptoms.Overactive bladder, differential diagnosis, and clinical utility of fesoterodineNew developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Development of oxybutynin chloride topical gel for overactive bladderSocial, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trialOxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats.Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?β3-receptor agonists for overactive bladder--new frontier or more of the same?Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence.Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?Persistence with mirabegron therapy for overactive bladder: A real life experience.Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.Drugs for the overactive bladder: are there differences in persistence and compliance?Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.Time-to-effect with darifenacin in overactive bladder: a pooled analysis.A new tool for self-evaluation of adherence to antimuscarinic drugs treatment in patients with urinary incontinence.Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons.Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.Effects of urine alkalinization with sodium bicarbonate orally on lower urinary tract symptoms in female patients: a pilot study.Effectiveness of a new tool for self-evaluation of adherence to antimuscarinic drug treatment in older patients of both sexes with urge incontinence.Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up.
P2860
Q27000698-51CE52F9-9582-4068-ADFA-BBE8A26053CEQ34012234-2D64725E-D997-429A-8CF0-EFD6787F2BD5Q34610640-13201E6A-6725-4CF1-8C70-6120F4A4E310Q34961830-65AADD81-5455-432D-8098-B4EDBA0C8A39Q34982181-C76AD293-BDFA-40CB-89A8-9C6BDE1AECF2Q35137862-254C8CC0-700D-490B-A9E8-6C52FBB393C0Q35572326-4603AB87-DF3F-4BC9-8463-D97069E79BF0Q36328670-A0279B49-4889-4453-990A-B8F98B02461EQ36429651-BC121DF5-EEB6-407A-B532-77F4B6CD4D4AQ36789948-3D3DCEE4-1D62-45F1-A6F1-A1B2B00C0707Q37283717-9512C4B3-662B-4602-8D7C-528BC731CC9BQ37373376-715A1DCB-9E70-4343-803D-43050BA6A936Q37399563-C599E4CA-51A3-4065-8157-FACE814A5E15Q37461417-3D462EB2-D612-4362-B134-666378AA6329Q37642772-8F89BE09-72D1-46CF-BC9B-3E36360EB9DAQ37671696-8626E00B-3173-4ED0-9823-542AC37BEFE6Q37728633-D54AC815-E556-4D0E-A890-AD7A1927576EQ37947438-D0D292C0-9631-477C-B7CD-DF01AA0E64CCQ38107167-A9876D78-FB8D-45E4-88ED-05632EEA10D0Q38217760-53BF3146-EEC6-4433-824C-82F5C96532A0Q38827514-51A3CFCE-8694-43C7-89B7-BC3946C46B8BQ38993756-D3D62854-3FB7-467D-81F1-8B5E4A1354DDQ39046374-BA9A1F20-3461-4DCD-9786-507023CE0413Q39475700-A0F010FE-AC4A-4FF7-A4AB-6FE53898186CQ40210488-A6DF554C-99FF-43E6-A3F0-0732852BE49FQ40691097-A8743DF0-3C00-4B72-AC31-CB2786032A80Q42332340-F2D375C4-8194-4AEE-93B8-F120E6A530ECQ42665431-8D3F1A94-9ACE-4328-9692-F139D85C2B76Q44874780-B7FA67CA-B380-41CE-827C-FBA1CA1652C8Q46351979-F2C1A81C-84E6-4338-8F4C-BD44411C6589Q46453096-BC5E933A-BFF9-488E-9935-2B7BBF579833Q47172054-14588616-2931-458B-BBA3-1400E62E0F14Q47546972-DB6A9260-28F5-4408-B591-A0251D4B552FQ47585163-C205EDDC-CC0C-4AA5-AC49-88D1D3CBA2E9Q47620678-54A7E998-DC77-40C1-8C14-AA47D151F98BQ47690070-1DDDBB86-8E76-4F8B-A0B2-6CA2DF917ABAQ48030253-7EB149C8-F48F-486A-8FE7-090C79BEF972Q48261630-8FB75F60-C0AE-453C-83E6-C0322AA969B4Q48300325-2CF509F0-506A-4B99-AB94-CBD776192169Q48390526-52C33428-D040-4E94-B644-E86534218385
P2860
A review of adherence to drug therapy in patients with overactive bladder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A review of adherence to drug therapy in patients with overactive bladder.
@en
A review of adherence to drug therapy in patients with overactive bladder.
@nl
type
label
A review of adherence to drug therapy in patients with overactive bladder.
@en
A review of adherence to drug therapy in patients with overactive bladder.
@nl
prefLabel
A review of adherence to drug therapy in patients with overactive bladder.
@en
A review of adherence to drug therapy in patients with overactive bladder.
@nl
P2093
P1433
P1476
A review of adherence to drug therapy in patients with overactive bladder.
@en
P2093
Adrian Wagg
Con Kelleher
David Castro-Diaz
Ian Milsom
Linda Cardozo
Mark Vierhout
Mike Kirby
Montserrat Espuna Pons
Philip Van Kerrebroeck
Ramandeep K Basra
P304
P356
10.1111/J.1464-410X.2008.07769.X
P577
2008-07-04T00:00:00Z